Associations between Brain Reserve Proxies and Clinical Progression in Alzheimer's Disease Dementia.
Hyung-Jun YoonSeung-Gon KimSang Hoon KimJong Inn WooEun Hyun Seonull For The Alzheimer's Disease Neuroimaing InitiativePublished in: International journal of environmental research and public health (2021)
The purpose of this study was to investigate whether brain and cognitive reserves were associated with the clinical progression of AD dementia. We included participants with AD dementia from the Alzheimer's Disease Neuroimaging Initiative, provided they were followed up at least once, and candidate proxies for cognitive (education for early-life reserve and Adult Reading Test for late-life reserve) or brain reserve (intracranial volume [ICV] for early-life reserve and the composite value of [18F] fluorodeoxyglucose positron emission tomography regions of interest (FDG-ROIs) for late-life reserve) were available. The final analysis included 120 participants. Cox proportional hazards model revealed that FDG-ROIs were the only significant predictor of clinical progression. Subgroup analysis revealed a significant association between FDG-ROIs and clinical progression only in the larger ICV group (HR = 0.388, p = 0.028, 95% CI 0.167-0.902). Our preliminary findings suggest that relatively preserved cerebral glucose metabolism might delay further clinical progression in AD dementia, particularly in the greater ICV group. In addition to ICV, cerebral glucose metabolism could play an important role as a late-life brain reserve in the process of neurodegeneration. Distinguishing between early- and late-life reserves, and considering both proxies simultaneously, would provide a wider range of factors associated with the prognosis of AD dementia.
Keyphrases
- positron emission tomography
- early life
- mild cognitive impairment
- computed tomography
- pet ct
- cognitive impairment
- pet imaging
- resting state
- cerebral ischemia
- subarachnoid hemorrhage
- cognitive decline
- healthcare
- randomized controlled trial
- functional connectivity
- quality improvement
- clinical trial
- brain injury
- working memory
- blood brain barrier
- phase iii